|
|
|
|
|
Advertisement |
Accelerate the launch of your pharma product, while also easing financial and administrative burdens with 3PL Title Model.
 Learn more
|
|
|
| Advertisement |
2017 Real-World Evidence Benchmark Survey
Deloitte's 2017 Real-World Evidence Benchmark Survey shows that life sciences companies are making some progress in using RWE but still have opportunities to expand applications across the value chain, consider new channels to access RWD, and improve their overall capabilities.
 Explore this research Today!
|
| Europe |
 |
|
A Long Summer of Drug Pricing Tension Looms |
In the hothouse atmosphere of European governments' anxieties over ever more expensive medicines, recent weeks have seen perspiration breaking out on the brows of ministers, officials and drug company executives, writes Reflector
… /Read more/ |
|
|
| Advertisement |
The Importance of Stakeholder Research in Rare Disease Drug Development
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications. With this increase Rare Disease Drug Development and broadening class of products, including some that target the same mutation or molecular defect, sponsors face new and significant market access challenges in securing reimbursement. Sponsored by Covance
 Learn more
|
|
| Advertisement |
Launch Excellence V: Surviving and thriving in a specialized world
Live Webinar: Wednesday, June 14 at 10:00am EDT
 Register now
|
|
| Regulatory |
 |
|
FDA Looks to Advance Regenerative Medicine |
The Center for Biologics Evaluation and Research (CBER) is gearing up to facilitate the development and approval of regenerative medicine advanced therapies, as defined by the 21st Century Cures Act, writes Jill Wechsler
… /Read more/ |
|
|
| Advertisement |
Emerging Biopharma and Rare Disease: Finding a Needle in a Haystack
Data-driven Patient Recruitment Solutions
Live Webinar: Thursday, June 8 at 2:00pm EDT
 Register now
|
|
|
|
| Calendar |
|
|
|
| Advertisement |
Through the Patient's Eyes - Needs, Behaviors and the Science Behind it All
Live Webcast: Wednesday, June 21 at 11:00am EDT
 Register now
|
|
|
| Advertisement |
Coming to terms with Patient Centricity
Live Webinar: Tuesday, June 20 at 12:00pm EDT
 Register now
|
|
|
|
| Competitive Advantage |
 |
|
Reinventing the Role of Medical Affairs |
As digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator, write Loic Plantevin, Christoph Schlegel and Maria Gordian
… /Read more/ |
|
|
| Advertisement |
Talking the Patients' Language – the importance of effective, patient-centered engagement
Live Webinar: Tuesday, June 6 at 8:00am EDT
 Register now
|
|
| Outlook |
|
| Advertisement |
Best Practices for Managing Regulated Promotional Content
On Demand
 Learn more
|
|
|
| Industry update |
| //Constellation Pharmaceuticals (Cambridge, MA) appointed Jigar Raythatha as President and CEO. //Concert Pharmaceuticals (Lexington, MA) announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking. //Genecentric Therapeutics (Durham, NC) appointed Walter M. Capone as Chief Business Officer and added Ellen Lubman to its Board of Directors. //Rosa & Co. (San Carlos, CA) appointed Matt Marano as Senior Vice President of Business Development// |
| Advertisement |
Winning the RAT race: A new Center of Excellence to drive development of regenerative medicines
On Demand
 Learn more
|
|
|
|
|
